Rituxan

Latest articles

4d
EuroNews
Poor test results for Roche cloud growth prospectsMoreover, the first of a threatened flood of biosimilar copies of Roche’s $22-b
EuroNews / Posted 4 days ago
Moreover, the first of a threatened flood of biosimilar copies of Roche’s $22-billion-per-year trio of cancer drugs, Rituxan, Avastin and Herceptin, have now been approved in Europe and the United States. Chief Executive Severin Schwan has... Read more
10d
FOX Business
How Biogen Inc. Makes Most of Its Moneythere's potential for some growth ahead. Close, but only half a cigar It shou
FOX Business / Posted 10 days ago
there's potential for some growth ahead. Close, but only half a cigar It should be noted that Biogen's anti-CD20 drugs, Rituxan and Gazyva, combined for $1.04 billion of sales, besting Tecfidera. However, the company shares revenue on those two... Read more
10d
FOX Business
How Biogen Inc. Makes Most of Its Moneythere's potential for some growth ahead. Close, but only half a cigar It shou
FOX Business / Posted 10 days ago
there's potential for some growth ahead. Close, but only half a cigar It should be noted that Biogen's anti-CD20 drugs, Rituxan and Gazyva, combined for $1.04 billion of sales, besting Tecfidera. However, the company shares revenue on those two... Read more
13d
Arkansas Democrat-Gazette
Drugmakers prepare for patent lossesthe next two years, which account for more than $20 billion of its $51.4 billio
Arkansas Democrat-Gazette / Posted 13 days ago
the next two years, which account for more than $20 billion of its $51.4 billion in annual sales. Roche's leukemia therapy Rituxan, which generated $7.24 billion last year in sales, loses patent protection this year, according to Bernstein. Out of... Read more
14d
The Morning Call
Why drugmakers aren't sweating the next wave of patent lossesthe next two years, which account for more than $20 billion of its $51.4 billio
The Morning Call / Posted 14 days ago
the next two years, which account for more than $20 billion of its $51.4 billion in annual sales. Roche's leukemia therapy Rituxan, which sold 7.3 billion Swiss francs ($7.24 billion) last year, loses patent protection this year, according to... Read more
14d
Business Standard India
Royalty Pharma, PE firm that quietly profits on top-selling drugsstart what became Royalty Pharma. After assembling a diversified royalty portf
Business Standard India / Posted 14 days ago
start what became Royalty Pharma. After assembling a diversified royalty portfolio — including the popular anticancer drug Rituxan, which helped triple the value of early investments — Legorreta raised $190 million in debt in 2003. As Royalty... Read more
16d
iol.co.za
Drug-makers losing billions in salesthe next two years, which account for more than $20 billion of its $51.4 billio
iol.co.za / Posted 16 days ago
the next two years, which account for more than $20 billion of its $51.4 billion in annual sales. Roche’s leukemia therapy Rituxan, which sold 7.3 billion Swiss francs ($7.24 billion), last year, loses patent protection this year, according to... Read more
17d
Swissinfo
Why Drugmakers Aren't Sweating the Next Wave of Patent Lossesthe next two years, which account for more than $20 billion of its $51.4 billio
Swissinfo / Posted 17 days ago
the next two years, which account for more than $20 billion of its $51.4 billion in annual sales. Roche’s leukemia therapy Rituxan, which sold 7.3 billion Swiss francs ($7.24 billion) last year, loses patent protection this year, according to... Read more
23d
FOX Business
Illumina, Inc. vs. Roche Holding Ltd.can shrink overnight. Patents provide the primary moat for Roche. Last year, t
FOX Business / Posted 23 days ago
can shrink overnight. Patents provide the primary moat for Roche. Last year, three cancer drugs -- Avastin, Herceptin, and Rituxan -- accounted for around 50% of all sales. It's great to have such important drugs on your roster, and Roche obviously... Read more
23d
FOX Business
Illumina, Inc. vs. Roche Holding Ltd.Reading Below Patents provide the primary moat for Roche. Last year, three can
FOX Business / Posted 23 days ago
Reading Below Patents provide the primary moat for Roche. Last year, three cancer drugs -- Avastin, Herceptin, and Rituxan -- accounted for around 50% of all sales. It's great to have such important drugs on your roster, and Roche obviously... Read more
23d
Medical News Today
Human antibody bolsters cancer drug performanceto the medication might restore its cancer-killing capabilities. Rituximab, wh
Medical News Today / Posted 23 days ago
to the medication might restore its cancer-killing capabilities. Rituximab, which is sometimes sold under the brand name Rituxan, is used to treat certain autoimmune diseases and some types of cancer. Rituximab is not a chemotherapy drug, but... Read more
24d
FOX Business
Dova Pharmaceuticals Targets a 9-Figure Opportunity, but Should You Buy Its IPO?for thrombocytopenia and they're typically treated with corticosteroids or intr
FOX Business / Posted 24 days ago
for thrombocytopenia and they're typically treated with corticosteroids or intravenous immunoglobin. Off-label use of Rituxan, removing the spleen, or a class of drugs known as TPO-RA's may also be used in the second-line setting. It's the... Read more
24d
FOX Business
Dova Pharmaceuticals Targets a 9-Figure Opportunity, but Should You Buy Its IPO?for thrombocytopenia and they're typically treated with corticosteroids or intr
FOX Business / Posted 24 days ago
for thrombocytopenia and they're typically treated with corticosteroids or intravenous immunoglobin. Off-label use of Rituxan, removing the spleen, or a class of drugs known as TPO-RA's may also be used in the second-line setting. It's the... Read more
24d
FOX Business
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)J&J is using price discounts and other promotional strategies in an attempt to
FOX Business / Posted 24 days ago
J&J is using price discounts and other promotional strategies in an attempt to preserve market share for Remicade.No. 4: Rituxan Roche again makes the list of the world's top-selling prescription drugs with Rituxan, with partner Biogen taking a... Read more
24d
FOX Business
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)J&J is using price discounts and other promotional strategies in an attempt to
FOX Business / Posted 24 days ago
J&J is using price discounts and other promotional strategies in an attempt to preserve market share for Remicade.No. 4: Rituxan Roche again makes the list of the world's top-selling prescription drugs with Rituxan, with partner Biogen taking a... Read more
30d
Newsmax
FDA Approves New Drug for Blood Cancershave approved a more convenient version of a blockbuster drug for treating thre
Newsmax / Posted 30 days ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
30d
Business Wire
Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017-2027and promising segment of the overall pharmaceutical industry. Characterized by
Business Wire / Posted 30 days ago
and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®) and a robust pipeline of product therapy candidates, the market is... Read more
1m
CTV News
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
CTV News / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
KTVN Reno
FDA approves quicker-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
KTVN Reno / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
Darien News-Review
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
Darien News-Review / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
The Fairfield Citizen
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
The Fairfield Citizen / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
FOX Business
FDA approves quicker-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
FOX Business / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
FOX Business
FDA approves quicker-administer drug for blood cancersversion of a blockbuster drug for treating three common blood cancers. Continu
FOX Business / Posted a month ago
version of a blockbuster drug for treating three common blood cancers. Continue Reading Below The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
Stamford Advocate
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
Stamford Advocate / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
Chattanooga Times Free Press
FDA approves quicker-to-administer drug for blood cancersThis photo provided by Genentech, the Roche Group's biologic drug unit, shows v
Chattanooga Times Free Press / Posted a month ago
This photo provided by Genentech, the Roche Group's biologic drug unit, shows vials of Rituxan Hycela. On Thursday, June 22, 2017, the Food and Drug Administration approved Rituxan Hycela, a more convenient version of a blockbuster drug for treating... Read more
12 related articles
1m
The Greater New Milford Spectrum
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
The Greater New Milford Spectrum / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
The New Canaan News
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
The New Canaan News / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
Connecticut Post
FDA approves quicker-to-administer drug for blood cancershave approved a more convenient version of a blockbuster drug for treating thre
Connecticut Post / Posted a month ago
have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group's Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take... Read more
12 related articles
1m
Channel NewsAsia
FDA approves more convenient form of Roche blood cancer drugREUTERS: U.S. health regulators on Thursday approved a new formulation of Roche
Channel NewsAsia / Posted a month ago
REUTERS: U.S. health regulators on Thursday approved a new formulation of Roche's big-selling cancer drug Rituxan for three common types of blood cancers that allows for relatively quick administration via injection under the skin in place of a... Read more
12 related articles

In this news